The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Andrew Tsai - Jefferies LLC - Analyst
: Hi, good afternoon. Congrats on a nice quarter, and thanks for taking my questions. The first one is on SPN-830, the apomorphine pump. Congrats
on resubmitting that. Just wanted to gauge your level of confidence it will be approved this time.
It's kind of interesting, since we know the competitor also received a CR recently. So maybe talk about your level of confidence about this? Thanks.
Question: Andrew Tsai - Jefferies LLC - Analyst
: Makes sense. Thanks. And shifting to 817, we're going to have the full Phase 2a data cut later this year. Can you remind us, I think 19 of 41 patients
completed the maintenance period. How many more patients do you think will be completing that maintenance period? And how many more
specifically at the 3 to 4 milligram dose, the high doses?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 06, 2024 / 8:30PM, SUPN.OQ - Q2 2024 Supernus Pharmaceuticals Inc Earnings Call
Question: Andrew Tsai - Jefferies LLC - Analyst
: And then last one is on 820, the depression asset. You're having pulsatile data in 40 patients with MDD later this year. Can you just remind us how
long the study is and what kind of MADRS or HAM-D efficacy benefit you want to see at the end of the study? What would be positive data to you
and why?
Question: Andrew Tsai - Jefferies LLC - Analyst
: Thanks again.
Question: David Amsellem - Piper Sandler & Co - Analyst
: Thanks. A couple of questions on Qelbree. So with the back-to-school season coming up, help us understand your expectations for acceleration
Question: David Amsellem - Piper Sandler & Co - Analyst
: And if I just may sneak in a quick follow-up. The gross-to-net, I mean it's getting below 50%, I mean, which is better than what you had cited as a
target in the past. I mean is that 45% to 50% -- and just to be clear, that's your view of steady-state gross-to-net over the long term for the product?
And maybe I'll ask it differently. Is there room for even further improvement?
Question: David Amsellem - Piper Sandler & Co - Analyst
: Okay, that's helpful. Thank you.
Question: Stacy Ku - TD Cowen Inc - Analyst
: Wonderful. I'm Thanks so much for taking our questions. What a great quarter for Qelbree and just a solid net value for prescription. So we have a
few follow-ups. Just for Q1, can you just talk a little bit more about what approach you're trying to do to grab share in the back-to-school season?
So just to clarify, you said the next quarter or so you could see a benefit in gross-to-net, but do you think any of these back-to-school plans could
Question: Stacy Ku - TD Cowen Inc - Analyst
: Thank you.
Question: Annabel Samimy - Stifel Financial Corp - Analyst
: Hi. Thanks for taking my question. Great quarter on Qelbree. I just want to put a finer point on the adult versus pediatric. To what extent is the adult
population driving some of maybe the improved pricing?
Obviously they have higher doses, so potentially a higher price point. And given that that's where a good chunk of the growth was and some of
your efforts had been lying in that area, can you maybe share some of the feedback that you're getting from the adult population?
Is this an area that you can continue to push? And is there any pushback from the adults in terms of whether they're favoring a stimulant versus a
non-stimulant, if they're still transitioning with lower doses than you expected, et cetera, et cetera.
Just trying to understand why, with the growth that you have, why it's still sitting at 32% of your total prescriptions and also with the efforts that
you're making last quarter. Thanks.
Question: Annabel Samimy - Stifel Financial Corp - Analyst
: Got it. And maybe you can just share what your expectations are for the level of penetration you might have in that adult population in either for
the year or for the long-term outlook. Is this still going to be a 32% type of -- well, I mean is it going to account still for about 32% of your prescriptions
or do you expect that number to continue to go up through the year?
Question: Annabel Samimy - Stifel Financial Corp - Analyst
: Okay. And if I can just ask a quick question on SPN-830, I guess this is several times now through the review process. Are there any indications from
FDA on the breadth of the population that might be included in the label? I'm not sure if you ever got to that point where you got to label discussions,
but is FDA considering a broader label or is it still mostly in the severe camp?
Question: Annabel Samimy - Stifel Financial Corp - Analyst
: Great, thank you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 06, 2024 / 8:30PM, SUPN.OQ - Q2 2024 Supernus Pharmaceuticals Inc Earnings Call
| 
